Unique formulation for PROLONGED circulation1
The ONIVYDE® liposome is designed to protect irinotecan from EARLY CONVERSION to SN-385
- Irinotecan is converted to the active metabolite SN-38 by carboxylesterases
- ONIVYDE® consists of a lipid bilayer vesicle, or liposome, that encapsulates irinotecan in an aqueous space1
See the ONIVYDE® liposome in action
The ONIVYDE® liposome is designed to PROLONG THE CIRCULATION OF IRINOTECAN before conversion to its active form1
- The half-life (t1/2) of total irinotecan following administration of ONIVYDE® 70 mg/m2 is 25.8 hours1
95% of irinotecan remains contained within the liposome during circulation.1
- The ratio between total and encapsulated forms did not change from 0 to 169.5 hours post-dose1
Intratumoral exposure at a lower dose1
In mice bearing human tumor xenografts, ONIVYDE® achieved similar intratumoral exposure at a 5-fold lower dose of irinotecan hydrochloride.1
Intended for healthcare professionals
The information within this site is intended for US healthcare professionals only.
Please choose an option below to continue.
NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.
YOU ARE NOW LEAVING ONIVYDE.COM
You are about to leave ONIVYDE.com and visit a third-party website. The website will load automatically unless you click Cancel.